Skip to main content
Premium Trial:

Request an Annual Quote

GSK Licenses Compendia's Oncomine for Cancer Drug Studies

NEW YORK (GenomeWeb News) – GlaxoSmithKline has licensed Compendia Bioscience’s Oncomine Enterprise Edition database for use in its cancer research programs, Compendia said today.
The pharmaceutical company has licensed the database, which is an extension of the Oncomine line, under a two-year agreement.
The Oncomine database is a compendium of nearly 26,000 gene expression and DNA copy number profiles taken from scientific literature and other public sources, and it uses gene sets to enable “researchers to discover and explore new biology based on signatures related to drugs and/or disease pathways,” Compendia said.
Financial terms of the agreement were not released.

The Scan

Transcriptomic, Epigenetic Study Appears to Explain Anti-Viral Effects of TB Vaccine

Researchers report in Science Advances on an interferon signature and long-term shifts in monocyte cell DNA methylation in Bacille Calmette-Guérin-vaccinated infant samples.

DNA Storage Method Taps Into Gene Editing Technology

With a dual-plasmid system informed by gene editing, researchers re-wrote DNA sequences in E. coli to store Charles Dickens prose over hundreds of generations, as they recount in Science Advances.

Researchers Model Microbiome Dynamics in Effort to Understand Chronic Human Conditions

Investigators demonstrate in PLOS Computational Biology a computational method for following microbiome dynamics in the absence of longitudinally collected samples.

New Study Highlights Role of Genetics in ADHD

Researchers report in Nature Genetics on differences in genetic architecture between ADHD affecting children versus ADHD that persists into adulthood or is diagnosed in adults.